Oropharyngeal Cancer Market is segmented By Treatment (Immunotherapy, Chemotherapy), By Type (HPV-Positive Oropharyngeal Cancer, HPV-Negative Orophary....
Market Size in USD
CAGR5.4%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.4% |
Market Concentration | High |
Major Players | Innate Pharma, GlaxoSmithKline, Debiopharm, Checkpoint Therapeutics, Quadriga BioSciences |
The oropharyngeal cancer market is estimated to be valued at USD 2.11 Bn in 2024 and is expected to reach USD 3.05 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. According to recent statistics by WHO, over half a million new cases of oropharyngeal cancer are reported annually. The increasing prevalence of risk factors such as tobacco consumption, human papillomavirus (HPV) infection and alcohol use is contributing significantly to the disease burden.